Should women under 50 be screened for breast cancer? by Moss, S
Minireview
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Despite some controversy in recent years, the majority of experts agree on the evidence for effectiveness of breast screening by
mammography for women aged 50 years and above, but for those under 50 years, the picture is much less clear. However, the issue
remains of importance both to policy makers and to individual women; although the incidence of breast cancer is lower at younger
ages, the life years lost due to cancers diagnosed below 50 years amount to a third of all those lost due to the disease.
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This article summarises the current position in different countries,
and reviews the most recent evidence on effectiveness of screening
women below 50 years from randomised trials. It has not been
conducted as a systematic review or meta-analysis, of which a
number have been performed. It also addresses the range of
potential disadvantages of screening with particular reference to
this age group.
CURRENT SCREENING GUIDELINES
The uncertainty is reflected in the variation in current guidelines
among countries for screening women below 50 years for breast
cancer. A summary of guidelines used in 22 countries, from a
survey conducted in 1995 by the International Breast Screening
Network (Shapiro et al, 1998), reported that while a majority of
countries or pilot projects had a lower age limit of 50 years, a
number involved a lower limit of 40 years, although in countries
such as Sweden and Australia policy can vary by county or state.
Japan, which does not use mammography, reported a lower age
limit of 30 years. In Sweden, the recommended screening interval
is 1.5 years for women aged 40– 49 years compared with 2 years for
those aged 50 years and above. In the US, the recommendation
(updated in February 2002) from the US Preventive Services Task
Force is for ‘screening mammography with or without clinical
breast examination’ (CBE) every 1 or 2 years for women aged 40
years and above (US Preventive Services Task Force, 2002). The
age range was extended below 50 years despite the finding that ‘the
strongest evidence of benefit and reduced mortality is among
women aged 50– 69 years’. The US National Cancer Institute
continues to recommend mammography for women in their 40s
and older, while the American Cancer Society recommends ‘yearly
mammograms’ (plus CBE) starting at 40 years (Smith et al, 2003).
In 2001, the Canadian Task Force on Preventive Health Care
concluded that ‘upon reaching the age of 40 years, Canadian
women should be informed of the potential benefits and risks of
screening mammography and assisted in deciding at what age they
wish to initiate the manoeuvre’ (Ringash, 2001).
The IARC Handbook of Cancer Prevention on breast cancer
screening, published in 2002, concluded that the marginal cost-
effectiveness of expanding a programme to younger women (aged
40–49 years) greatly depends on its effect on reducing breast
cancer mortality as estimated from randomised controlled trials,
‘and that it is likely to be more cost-effective to make other
changes’.
THE EFFECTIVENESS OF SCREENING IN YOUNGER
WOMEN
Evidence from randomised trials
Of the eight randomised trials, which have so far reported
mortality results and included women aged 40–49 years at entry,
only one (Miller et al, 1992) was designed specifically to study the
effectiveness of screening in this age group. The remainder
included cohorts of women between 40 or 45 and 64 years or
older at entry. The relevant trials are summarised in Table 1 (the
trial in Malmo, which included two cohorts, being included as two
separate entries).
There is evidence accumulating from these trials of a possible
benefit of screening in women under the age of 50 years. A number
of meta-analyses of these trials have been performed (Smart et al,
1995). The most recent of these, published in 1997, included an
average follow-up time of 12.7 years and estimated a significant
18% reduction in mortality from breast cancer among women aged
40–49 years at entry, invited to screening mammography (RR 0.82,
95% CI 0.71– 0.95) (Hendrick et al, 1997). An analysis restricted to
the five Swedish trials estimated a 29% mortality reduction among
women invited to screening (RR 0.71, 95% 0.57–0.89).
The significant benefit seen in this latest meta-analysis is due
primarily to updated results from trials in Gothenburg and Malmo.
The Gothenburg trial began in 1983/1984, and included approxi-
mately 26 000 women aged 39–49 years, of whom 11 724 were
randomised to an intervention arm invited for screening by
mammography every 18 months. Those in the control arm were
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invited at the time of the fifth screen of the intervention arm (6–7
years after the date of entry). Owing to the small sample size, a
significant reduction was not apparent until 12 years of follow-up,
at which time a 45% reduction in mortality from breast cancer was
observed in the intervention arm (RR 0.55, 95% CI 0.31–0.96)
(Bjurstam et al, 1997).
The Malmo trial contained approximately 8000 women under 50
years at entry in the initial cohort randomised in 1977–1978, and a
further 17 000 women randomised at age 45– 48 years between
1978 and 1990. Pooling the two cohorts, there was a statistically
significant reduction in breast cancer mortality in the intervention
arm at 12 years of follow-up (RR 0.64, 95% CI 0.45–0.89)
(Andersson and Janzon, 1997).
An updated overview of the five Swedish studies, published in
2002, did not include the Kopparberg part of the Two-County trial,
but did include a continuation of the Malmo trial (Nystrom et al,
2002). In this overview, the median follow-up time was 15.8 years;
there was a 20% reduction in women aged 40–49 years at entry
(RR 0.80, 95% CI 0.63–1.01), and an analysis by 5 year age groups
found no significant heterogeneity.
The Canadian National Breast Screening Study 1 was designed to
evaluate the efficacy of the combination of annual mammography,
physical examination and the teaching of breast self-examination
in reducing the rate of death from breast cancer among women
aged 40– 49 years at entry. Between 1980 and 1985, the trial
randomised 50 430 women aged 40–49 years to an arm offered
annual mammography and physical examination (MP), or to an
arm offered usual care (UC) after an initial physical examination.
After a mean of 8.5 years of follow-up, there was a nonsignificant
3.6% increase in breast cancer mortality in the MP group (RR 1.36,
95% CI 0.84–2.21); at a mean of 13 years follow-up the rate ratio
was 0.97 (95% CI 0.74–1.27). An adjustment taking account of
mammography done outside the study yielded a rate ratio of 1.06
(95% CI 0.80– 1.40) (Miller et al, 2002).
This trial made use of a volunteer population, which may not be
representative of the general population, and there has been debate
over the quality of mammography, and over the effect of the initial
examination and education in the control arm. A major drawback
of the study has been the lack of statistical power, in part due to
lower than anticipated mortality in the control arm, with the result
that even after 13 years the confidence intervals are wide (Kopans
et al, 1994).
Interpretation of results
The interpretation of the various trial results has been widely
debated. Differences between the stage or size distribution of
cancers in the control arms have been cited as explaining observed
differences in benefit between trials (Narod, 1997), but despite
differences in study design there is no statistically significant
heterogeneity (Hendrick et al, 1997). Since the effect of screening
on mortality from breast cancer takes a number of years to become
apparent, and all the trials have invited women for routine
rescreening at intervals ranging from 18 to 33 months, it is difficult
to separate the effect of screening examinations, which took place
above and below 50 years. Analyses by age at diagnosis are
complicated by the effect of lead-time, the length of time by which
diagnosis has been advanced for screen-detected cancers which
will lower the age at diagnosis.
The MISCAN simulation model has been used to estimate that
70% of the mortality reduction observed in the Swedish trials in
women aged 40– 49 years at entry was a result of screening these
women after they reached 50 years (de Koning et al, 1995), based
on a comparison of predicted with observed results. However, the
alternative assumption that screening under 50 years has the same
effect as that in older women could not be excluded on the basis of
this analysis.
This analysis was based on the observed breast cancer mortality
reduction of 10% in women aged 40 –49 years reported at that
time; with longer follow-up, the observed reduction is larger, and
further analyses are being conducted in order to update these
estimates (de Koning, personal communication).
Reasons for a possible lesser effect of screening in younger
women include lower sensitivity of mammography due to a higher
prevalence of dense tissue, and a tendency for tumours in young
women to be faster growing, implying a need for more frequent
screening (Tabar et al, 1995).
The results of a meta-analysis (which also included one case–
control study) suggested that the summary relative risk of
mortality from breast cancer in women aged 40– 49 years invited
for screening compared with those who were not was lower for
studies using two view mammography, and for studies with longer
follow-up (Kerlikowske et al, 1995).
It appears likely that there will be a benefit in terms of reduced
mortality from breast cancer associated with screening below 50
years, and that frequent (e.g. probably annual) screening will be
necessary to achieve this. However, the size of the benefit and the
age(s) at which screening should be performed are as yet
unknown. It is likely that any changes in the effectiveness of
screening with increasing age occur gradually, and the choice of
age 50 years for subgroup analyses is arbitrary (Kopans, 1998),
although this could be viewed as a surrogate for age at menopause.
Research in progress
A trial in progress in the UK has been designed specifically to
address the question of whether offering screening by mammo-
graphy from 40 years is effective in reducing mortality from breast
cancer, compared with the current national policy of inviting
women from the age of 50 years (Moss, 1999). A total of 160 000
women aged 40–41 years have been randomised in the ratio 2 : 1 to
a control arm or an intervention arm. Women in the latter are
Table 1 Randomised trials of breast screening
Study
Screening
interval
(months) CBE included Study
Length of
follow-up
(years)
Age range
at entry RR (95% CI)
HIP (Shapiro et al, 1988) 12 Yes 1963–1966 18 40–59 0.77 (0.53, 1.11)
Ostergotland (Nystrom et al, 2002) 24 No 1978–1981 17 38–49 1.05 (0.64, 1.71)
Kopparberg (Tabar et al, 2000) 24 No 1976–1978 17 40–49 0.76 (0.42, 1.40)
Malmo I (Nystrom et al, 2002) 18–24 No 1976–1978 19 45–49 0.74 (0.44, 1.25)
Malmo II (Nystrom et al, 2002) 18–24 No 1978–1990 12.7 43–49 0.64 (0.45, 0.89)
Gothenburg (Nystrom et al, 2002) 18 No 1982–1984 13 39–49 0.58 (0.35, 0.96)
Stockholm (Nystrom et al, 2002) 28 No 1981–1983 15 39–49 1.52 (0.80, 2.88)
Edinburgh (Alexander et al, 1999) 24 Yes (annual) 1978–1981 14 45–49 0.83 (0.54, 1.27)
NBSSa 1 (Miller et al, 2002) 12 Yes 1980–1985 12 40–49 0.97 (0.74, 1.27)
aMammography+CBE vs CBE alone. RR¼ relative risk; 95% CI¼ 95% confidence interval.
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offered annual mammography, until 48 years by two views at first
screen, and single view at subsequent screens unless indicated
otherwise. Women in the control arm receive usual medical care,
and those in both arms will receive their first invitation to screening
as part of the national programme between 50 and 52 years. The
trial began in 1991 and includes 23 centres, all of which are existing
NHS breast screening units. The trial is powered to detect a 20%
reduction in breast cancer mortality at 10 years of follow-up.
Meanwhile, surrogate outcome measures in terms of pathology
characteristics are being considered (Anderson et al, 2000).
COSTS OF SCREENING
The financial costs of mammography include those of screening
mammography, and further assessment and treatment costs, as
well as organisational costs for organised programmes. Screening
will also impact on treatment costs. The frequency of screening will
affect the cost across a given age range, and most comparisons of
cost-effectiveness have assumed a shorter screening interval (12–
18 months) below 50 years. However, the results of such
comparisons will vary according to the estimate of effectiveness
used. De Haes et al (1991) concluded that it would be more cost-
effective to shorten the screening interval for women aged 50– 70
years than to include 2 yearly screening for women aged 40– 49
years, based on the 8% mortality reduction then observed in the
Swedish Two Counties Study in women under 50 years. An
analysis in 1995 by Lindfors and Rosenquist (1995), using a
baseline estimate of mortality reduction for women aged 40– 49
years of 4% with biennial and 23% with annual mammography,
found that including women aged 40–49 years increased the
marginal cost per life year saved, but by less than some alternative
strategies. Salzmann et al (1997) assumed a 16% reduction in
breast cancer mortality starting at 50 years for women who begin
screening at 40 years and found that the cost-effectiveness of
mammography in women aged 40–49 years was about five times
that in older women.
ADVERSE EFFECTS OF SCREENING
In common with all screening tests, there are risks or disadvan-
tages associated with mammography, which need to be weighed
against any beneficial effect. Information on the adverse effects of
screening is essential to enable decisions to be reached by policy
makers on whether screening should be offered, and by women on
an individual basis on whether or not to attend.
False-positive results
Referral for further assessment of women who are subsequently
found to be free of cancer is one disadvantage of screening, which
will have a cost in terms of resources (Lidbrink et al, 1996), and to
the women referred. While attempts can be made to keep referral
rates low, there is a ‘trade off’ between specificity and sensitivity,
since if referral rates are too low, then the cancer detection rates
may also be low. Within the NHS breast screening programme,
referral rates tend to decrease with age, while cancer detection
rates increase in line with underlying incidence, with the result that
the positive predictive value of referral for assessment (i.e. the
probability that a woman referred will be found to have breast
cancer) is likely to be lower below 50 years. The cumulative risk of
a false-positive test (in women aged 40–69 years) has been
estimated in one US study to be 49% after 10 mammograms
(Elmore et al, 1998).
A number of studies have looked at the psychological effects of
the screening process on women, both for those screened as
normal and those referred for further assessment. Routine
attendance for screening in general seems to have little effect,
although some subgroups experience distress or increased anxiety
(Walker et al, 1994). The most significant effects are observed in
women referred for further assessment with false-positive results.
While most studies have found increased anxiety in those women
to be fairly short-lived (Cockburn et al, 1994; Ellman and Thomas,
1995; Lampic et al, 2001), some have reported long-term effects
(Lerman et al, 1991). However a false-positive result does not
appear to deter women from subsequent attendance for screening
(Lerman et al, 1991; Lightfoot et al, 1994). Anxiety is likely to be
minimised by the provision of appropriate information and by
reducing the time between initial screen and assessment. Timely
reporting of results may also reduce anxiety of the effects
associated with earlier stages in the screening process.
Exposure to radiation
The possible harmful effect of radiation resulting from mammo-
graphy in this age group has been widely debated (Law, 1995; Feig
and Hendrick, 1997; Young, 2001). Estimates of breast cancer risk
from low-dose radiation exposure are, by necessity, extrapolated
from studies of populations exposed to much higher doses, for
example atomic bomb survivors, or those receiving medical
radiation treatment, and these studies have suggested a greater
effect at lower ages of exposure. The estimated risk associated with
radiation will depend on whether a linear or quadratic dose
response model is chosen, and on whether an additive or relative
risk model is used. The average radiation dose for mammography
has reduced considerably over the past 15–20 years, and most
recent studies have estimated that the benefit of screening is likely
to outweigh the risk even in younger women (Law and Faulkner,
2001). Estimates of the average received dose in the UK Age trial are
of 2.5 mGy per oblique film and 2.0 mGy per craniocaudal film
(Young, 2001); in this study, age was not found to be a significant
factor affecting the dose to screened women aged above or below 50
years. A small proportion of women will receive higher doses for
reasons such as large breasts requiring more than one film per view.
Overdiagnosis
Another concern about screening is the possibility of over
diagnosis, by the detection of lesions which would otherwise not
have presented clinically during a woman’s lifetime. In the case of
breast screening, there is particular uncertainty over the natural
history of ductal carcinoma in situ (DCIS), which is infrequently
diagnosed in the absence of screening. In the Swedish Two
Counties randomised controlled trial, there was most evidence of
over diagnosis in women below 50 years (Tabar et al, 1992);
however, in that trial, the rate of detection of DCIS was
comparatively low. In the NHS breast screening programme, 4%
of cancers detected by screening in 2000/2001 in women aged
above 50 years were in situ (NHS Breast Screening Programme
Annual Review, 2002). The benefit of detecting and treating DCIS
remains an area of debate. A study in the UK found that the
majority of DCIS detected by screening was high-grade (Evans et al,
2001), and will, therefore, have a high probability of progression to
invasive cancer, but others have argued that progression rates may
be much lower (Jatoi and Baum, 1995; Baum, 1996). The IARC
handbook concludes that studies are required on the natural
history of DCIS, and on the impact of detection and treatment of
DCIS on the incidence of invasive cancers.
Screening in high-risk women
Of particular concern in many settings is the management of
women at increased risk of breast cancer due to family history of
the disease. It is estimated that such cases may account for between
5 and 10% of all cases (Eeles, 1999), and such women will be at
increased risk from a young age. It has been estimated that most of
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the excess risk of familial breast cancer occurs before 50 years
(Houlston et al, 1992) and it is generally recommended that
screening start 5–10 years before the earliest age at diagnosis of
affected family members.
Clearly if screening is effective in this age group, then the
absolute benefit in this subgroup will be greater, as will the cost-
effectiveness. Nevertheless, there is no more evidence for
effectiveness in high-risk women than in the general population.
In the UK, two studies are in progress to assess the effect of
screening in high-risk women. A randomised controlled trial is
comparing the sensitivity of mammography and magnetic
resonance imaging (MRI) in high-risk women identified from
genetics clinics (The UK MRI Breast Screening Study Advisory
Group, 2000). Magnetic resonance imaging does not involve the
use of ionising radiation, and hence may be of particular relevance
for screening at young ages. However, studies to date have
suggested high sensitivity but possibly low specificity. The cost of
the technique at present is such that its use is only under
consideration for women at high risk. A second study is evaluating
mammographic surveillance in women under 50 years with a
family history of breast cancer, with the aim of estimating the
difference in breast cancer mortality in screened compared with
unscreened women, and estimating the cost-effectiveness of
regular mammography in this group (MacKay et al, 2001).
Ultrasound has also been considered as a screening modality for
high-risk women, although there are doubts about both sensitivity
and specificity (Teh and Wilson, 1998). One recent study
concluded that MRI is likely to be superior as a screening method
for such women (Warner et al, 2001).
The increased radiation risk in these women will be affected by
the choice of model (additive or relative risk). It is possible that
some women genetically predisposed to breast cancer may also
have increased sensitivity to radiation, and if screened frequently
from a young age will also have increased total exposure. An
example is ataxia telangiectasia (AT), an inherited autosomal
recessive disease. Women who are AT gene carriers are also at
increased risk of developing breast cancer; however, there remains
debate as to whether this risk is increased by exposure to ionising
radiation (Swift et al, 1991; Wagner, 1992).
CONCLUSIONS
Until more information is available, it is difficult to inform either
policy makers (in terms of potential changes to national screening
programmes) or individual women on the balance between costs
and effectiveness of screening below 50 years. It has recently been
suggested, on the basis of age-specific incidence rates, that
screening in the UK should begin at 47 years (Sasieni and Cuzick,
2003), but the effect of such a policy in terms of mortality
reduction is not clear. For example, a number of the randomised
trials have observed a lesser effect in women aged 50– 54 years at
entry.
For individual women, full information on the possible benefits
and harmful effects of screening are essential to enable an
‘informed choice’ to be made and the need for accurate and
understandable information has been emphasised recently (Baines,
2003; Thornton et al, 2003). Only once further information on the
effectiveness of screening below 50 years is available, can the cost-
effectiveness of any change in policy can be estimated. Decisions
on national policy will then depend on comparing cost-effective-
ness with other policy options.
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